Pfizer agreed to a research collaboration and licensing deal with Enodia Therapeutics to discover and develop small-molecule inhibitors targeting Sec61, a translocon required for protein biogenesis. Enodia will run discovery and optimization work across multiple collaboration targets, while Pfizer will handle clinical, manufacturing, regulatory, and commercial activities after the collaboration term. The deal is valued at more than $500 million in total potential milestones and royalties, with Enodia receiving an upfront payment. The agreement adds another competition for validation in selective protein-synthesis modulation, an approach designed to preserve essential physiological functions while suppressing disease-driving clients.